Evaluation of the Safety and Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Femoral Fractures
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Certain types of fractures require surgical intervention that may involve the use of bone grafts or bone graft substitutes. Many of the materials used as bone graft substitutes suffer from disadvantages such as soft tissue invasion of the fracture area, inadequate blood supply, failure to encourage the production of bone and ectopic bone formation.
A guided bone regeneration (GBR) environment may help in solving these clinical concerns. GBR has been widely used in the field of dentistry since the 1980s to provide stable placement for dental implants.
The purpose of this study is to evaluate the safety, performance and initial efficacy of Regenecure's, AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
| Condition | Intervention | Phase |
|---|---|---|
|
Proximal (Subtrochanteric)Femoral Fractures Distal Femoral Fractures |
Procedure: AMCA Bone Membrane. |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Evaluation of the Safety Performance and Initial Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Proximal (Subtrochanteric) and Distal Femoral Fractures |
- Safety will be measured by evaluation of swelling, clinical signs of superficial or deep infection, pain in the operated area [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]To demonstrate the safety of the AMCA Bone membrane when used in the treatment of subtrochanteric and distal femoral fractures.
- efficacy will be assessed by radiographic evaluation. [ Time Frame: 12 months ] [ Designated as safety issue: No ]To evaluate the performance of the AMCA Bone membrane in providing enhanced healing of compromised fractures at risk of non-union.
| Estimated Enrollment: | 30 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: AMCA bone membrane
AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
|
Procedure: AMCA Bone Membrane.
AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: 18 to 65
- Males Females - non child bearing potential, or females of child-bearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent.
- Femoral subtrochanteric fracture and/or fracture of the distal third of the femur
The fracture is classified as one of the following:
- Closed fracture
- AO 31 A3, 33b + C1 + C2, and extending to the distal third (see Appendix A for AO fracture classification)
- Distal femur fracture will be treated with distal femoral anatomical locking, plate.
Proximal subtrochanteric femoral fracture will be treated with a cephalomedullary nail.
- Patients must be available for follow-up for a minimum of 12 months.
Exclusion Criteria:
- Active systemic or local infection.
- History of malignancy, radiotherapy, or chemotherapy for malignancy (except basal cell carcinoma of the skin)
- Active autoimmune disease.
- Any past or present immunosuppressive treatment.
- Open fractures.
- Administration of drugs that may interfere with bone metabolism:
- Accumulative dose of 150 mg total prednisone or any other gluco-corticosteroid for 7 days or more, within the last 6 months prior to the study;
- Calcitonin for 7 days or more within the last 6 months prior to the study;
- Bisphosphonates for 30 days or more within the last 12 months prior to the study;
- Bone therapeutic doses of fluoride for 30 days or more within the last 12 months prior to the study;
- Bone therapeutic doses of vitamin D or vitamin D metabolites for 30 days or more within the last 6 months;
- Current treatment with chemotherapeutic agents.
- History of metabolic bone disease (primary or secondary).
- Chronic renal insufficiency (defined by 50% increase of normal levels).
- Administration of marrow suppressive drugs (e.g., vancomycin).
- Alcohol abuse
- Drug addiction
- Smoking (more than 20 cigarettes per day)Bilateral fractures 19 Polytrauma with head injury and patient with periprosthetic fractures.
Contacts and Locations| Israel | |
| Hadassah Medical Organization, Orthopedic Surgery Department | Not yet recruiting |
| Jerusalem, Israel | |
| Contact: Amal Khoury, M.D 972-2-6423074 | |
| United Kingdom | |
| Academic Department Of Trauma and Orthipedic Surgery School Of Medicine , Universuty of Leeds | Not yet recruiting |
| Leeds, United Kingdom | |
| Contact: Peter Giannadis +441133922750 | |
| Study Chair: | Peter Giannoudis, Prof. | Leeds Hospital |
| Study Director: | Amal Khoury, M.D | Hadassah Medical Organization |
More Information
No publications provided
| Responsible Party: | RegeneCure, Ltd. |
| ClinicalTrials.gov Identifier: | NCT01687530 History of Changes |
| Other Study ID Numbers: | REGO01/12 |
| Study First Received: | September 9, 2012 |
| Last Updated: | September 18, 2012 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Femoral Fractures Fractures, Bone Wounds and Injuries Leg Injuries Tranexamic Acid Antifibrinolytic Agents Fibrin Modulating Agents |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Hemostatics Coagulants Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013